FDA Grants Fast Track Status to Oral Antiviral Bemnifosbuvir for COVID-19

The FDA has granted Fast Track designation to bemnifosbuvir, a nucleotide polymerase inhibitor, for the treatment of COVID-19.

Related Keywords

Jean Pierre Sommadossi ,Founder Of Atea Pharmaceuticals ,Atea Pharmaceuticals ,Drug Administration ,Fast Track ,